Quality of life, morbidity, mortality, and long-term prognosis after craniopharyngioma.

During the first months following diagnosis and treatment of childhood-onset craniopharyngioma, a substantial proportion of patients experience rapid and marked weight gain. This frequently progresses to severe hypothalamic obesity, which results from hypothalamic injury caused either by the tumor itself or by therapeutic interventions. Hypothalamic obesity should be regarded as one manifestation within the broader clinical spectrum of hypothalamic syndrome. Given the pivotal role of hypothalamic nuclei in maintaining physiological homeostasis, hypothalamic syndrome encompasses a wide range of disturbances, including hypothalamic-pituitary hormone deficiencies, disruption of circadian rhythms, impaired regulation of hunger, satiety, and thirst, as well as thermoregulatory dysfunction and cognitive, sleep-related, and psychosocial impairments. Consequently, affected individuals often develop persistent obesity, chronic fatigue, excessive daytime sleepiness, and mood disturbances, which may contribute to social withdrawal, academic challenges, reduced participation in daily activities, and impaired quality of life. Over time, these patients are at increased risk for metabolic syndrome, cardiovascular disease, sustained reductions in quality of life, and premature mortality. Historically, the management of hypothalamic syndrome has been challenging for both patients and clinicians, as conventional obesity treatments, including lifestyle modification, dietary interventions, and physical activity, have shown limited long-term efficacy. Pharmacological approaches have likewise been unsatisfactory, either due to insufficient effectiveness or unacceptable adverse effects leading to their withdrawal from clinical use. The therapeutic impact of central nervous system stimulants and glucagon-like peptide-1 receptor agonists in acquired hypothalamic obesity remains inconsistent and subject to ongoing debate. Recent findings from a randomized controlled trial provide, for the first time, encouraging evidence that setmelanotide, a melanocortin-4 receptor agonist, may substantially improve outcomes in patients with hypothalamic dysfunction associated with hypothalamic obesity. The emergence of a safe and effective pharmacological therapy that addresses not only metabolic abnormalities but also key psychosocial features, such as hyperphagia and overall quality of life, may represent a significant advancement in the management of this complex condition and offers the potential to meaningfully improve outcomes in this highly burdened and underserved patient population.